CNTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Centessa Pharmaceuticals (CNTA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong growth potential based on analyst ratings, positive sentiment from hedge fund activity, and a strategic focus on promising drug candidates. Despite insider selling, the company's long-term prospects and recent institutional interest make it a compelling investment.
The technical indicators are bullish. The MACD is positive and expanding, RSI is neutral at 65.625, and the moving averages (SMA_5 > SMA_20 > SMA_200) suggest an upward trend. Key resistance levels are at 25.413 and 26.192, with support at 22.892 and 22.113.
Hedge funds are significantly increasing their positions in CNTA, with a 325.14% increase in buying activity last quarter.
Analysts have raised price targets multiple times, with the latest targets reaching $38 and $62, citing strong momentum and undervaluation.
Braidwell's recent acquisition of a 1.75% stake for $54.73 million indicates institutional confidence.
The appointment of Mario Accardi as CEO signals a strategic focus on OX2R agonists and potential expansion into neuropsychiatric indications.
Insiders have been selling shares, with a 3778.14% increase in selling activity over the past month.
The company remains unprofitable, with a net income of -$54.89 million in Q3 2025.
In Q3 2025, Centessa reported no revenue growth (0% YoY), but net income improved by 28.96% YoY to -$54.89 million. EPS also improved by 10.81% YoY to -0.41, and gross margin remained at 100%. While the company is not yet profitable, the financials show signs of improvement.
Analyst sentiment is highly positive. Truist and Needham recently raised price targets to $38, citing strong momentum and potential acquisition interest. Oppenheimer has a price target of $62, highlighting the company's undervaluation and promising pipeline of orexin agonists. Analysts maintain Buy or Outperform ratings, reflecting confidence in the stock's long-term growth.
